1228 — Canbridge Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- HK$135.95m
- HK$140.75m
- CNY102.87m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 13.9 | 361 | 746 | 463 | 137 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 22.3 | 25 | 27.9 | 19.1 | 31.2 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 37.9 | 391 | 812 | 505 | 210 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8.86 | 15.6 | 29.5 | 145 | 109 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 88.5 | 586 | 893 | 702 | 395 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 43.7 | 108 | 186 | 278 | 328 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,079 | 2,332 | 199 | 393 | 435 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -991 | -1,746 | 693 | 309 | -39.8 |
Total Liabilities & Shareholders' Equity | 88.5 | 586 | 893 | 702 | 395 |
Total Common Shares Outstanding |